Teva announces launch of authorized generic of victoza® (liraglutide injection 1.8mg), in the united states

Parsippany, n.j.--(business wire)--teva pharmaceuticals, inc., a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), announced today the launch of an authorized generic of victoza®1 (liraglutide injection 1.8mg), in the united states. “by launching an authorized generic for victoza® (liraglutide injection 1.8mg), we are providing patients with type 2 diabetes another option for this important treatment,” said ernie richardsen, svp, head of u.s. commercial generics at te.
TEVA Ratings Summary
TEVA Quant Ranking